Influence of CYP3A5 and SLCO1B1 Polymorphisms on Atazanavir/r Concentrations in Thai HIV-Infected Patients

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2016). https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
   Google Scholar
• Thailand National Guidelines on HIV/AIDS Treatment and Prevention. Department of Disease Control, Ministry of Public Health (2017). https://aidssti.ddc.moph.go.th/contents/download/1768
   Google Scholar
• Croom KF , DhillonS , KeamSJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs69(8), 1107–1140 (2009).
   PubMed Web of Science ®Google Scholar
• Le Tiec C , BarrailA , GoujardC , TaburetA-M. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharm.44(10), 1035–1050 (2005).
   Google Scholar
• Gonzalez De Requena D , BonoraS , CantaFet al. Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. QC, Canada, April 28–30, 2005.
   Google Scholar
• Smith D , JeganathanS , RayJ. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin. Trials7(1), 34–38 (2006).
   PubMed Web of Science ®Google Scholar
• Cleijsen RM , VanDe Ende ME , KroonFPet al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J. Antimicrob. Chemother.60(4), 897–900 (2007).
   PubMed Web of Science ®Google Scholar
• Bertz RJ , PerssonA , ChungEet al. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naive. Pharmacotherapy33(3), 284–294 (2013).
   PubMed Web of Science ®Google Scholar
• Fabbiani M , DiGiambenedetto S , BraccialeLet al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J. Antimicrob. Chemother.64(1), 109–117 (2009).
   PubMed Web of Science ®Google Scholar
• Winston A , JoseS , GibbonsSet al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J. Antimicrob. Chemother.68(6), 1354–1359 (2013).
   PubMed Web of Science ®Google Scholar
• Punyawudho B , ThammajarukN , RuxrungthamK , AvihingsanonA. Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients. Int. J. Antimicrob. Agents49(3), 327–332 (2017).
   PubMed Web of Science ®Google Scholar
• Amadasi S , OdoliniS , FocaEet al. Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients. Curr. HIV Res.11(8), 642–646 (2013).
   PubMed Web of Science ®Google Scholar
• Venuto CS , MollanK , MaQet al. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J. Antimicrob. Chemother.69(12), 3300–3310 (2014).
   PubMed Web of Science ®Google Scholar
• Kile DA , MawhinneyS , AquilanteCL , RowerJE , Castillo-MancillaJR , AndersonPL. A population pharmacokinetic–pharmacogenetic analysis of atazanavir. AIDS Res. Hum. Retroviruses28(10), 1227–1234 (2012).
   PubMed Web of Science ®Google Scholar
• Goutelle S , BaudryT , GagnieuMCet al. Pharmacokinetic–pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients. Antimicrob. Agents Chemother.57(1), 517–523 (2013).
   PubMed Web of Science ®Google Scholar
• Stohr W , BackD , DunnDet al. Factors influencing lopinavir and atazanavir plasma concentration. J. Antimicrob. Chemother.65(1), 129–137 (2010).
   PubMed Web of Science ®Google Scholar
• Dailly E , TributO , TattevinPet al. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur. J. Clin. Pharmacol.62(7), 523–526 (2006).
   PubMed Web of Science ®Google Scholar
• Taburet AM , PikettyC , ChazallonCet al. Interactions between atazanavir–ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother.48(6), 2091–2096 (2004).
   PubMed Web of Science ®Google Scholar
• Barco E , NóvoaS. The pharmacogenetics of HIV treatment: a practical clinical approach. J. Pharmacogenomics Pharmacoproteomics4, 116 (2013).
   Google Scholar
• Calcagno A , CusatoJ , D’AvolioA , BonoraS. Genetic polymorphisms affecting the pharmacokinetics of antiretroviral drugs. Clin. Pharmacokinet.56(4), 355–369 (2017).
   PubMed Web of Science ®Google Scholar
• Bonora S , RusconiS , CalcagnoAet al. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). J. Antimicrob. Chemother.70(11), 3096–3099 (2015).
   PubMed Web of Science ®Google Scholar
• Phillips EJ , MallalSA. Personalizing antiretroviral therapy: is it a reality?Per. Med.6(4), 393–408 (2009).
   PubMed Web of Science ®Google Scholar
• Pavlos R , PhillipsEJ. Individualization of antiretroviral therapy. Pharmgenomics Pers. Med.5, 1–17 (2012).
   PubMedGoogle Scholar
• Avihingsanon A , VanDer Lugt J , KerrSJet al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin. Pharmacol. Ther.85(4), 402–408 (2009).
   PubMed Web of Science ®Google Scholar
• Chaikan A , ChierakulN , SaguenwongNet al. Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs. J. Int. AIDS Soc.11(1), P237 (2008).
   Google Scholar
• Avihingsanon A , TongkobpetchS , KerrSJet al. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. J. Acquir. Immune Defic. Syndr.69(1), e36–e37 (2015).
   PubMed Web of Science ®Google Scholar
• Lamba J , HebertJM , SchuetzEG , KleinTE , AltmanRB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet. Genomics22(7), 555–558 (2012).
   PubMed Web of Science ®Google Scholar
• Lamba JK , LinYS , SchuetzEG , ThummelKE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev.64, 256–269 (2012).
   Web of Science ®Google Scholar
• Anderson PL , AquilanteCL , GardnerEMet al. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J. Antimicrob. Chemother.64(5), 1071–1079 (2009).
   PubMed Web of Science ®Google Scholar
• Savic RM , Barrail-TranA , DuvalXet al. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin. Pharmacol. Ther.92(5), 575–583 (2012).
   PubMed Web of Science ®Google Scholar
• Wolking S , SchaeffelerE , LercheH , SchwabM , NiesAT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin. Pharmacokinet.54(7), 709–735 (2015).
   PubMed Web of Science ®Google Scholar
• Alam C , Whyte-AllmanSK , OmeragicA , BendayanR. Role and modulation of drug transporters in HIV-1 therapy. Adv. Drug Deliv. Rev.103, 121–143 (2016).
   PubMed Web of Science ®Google Scholar
• Rodriguez Novoa S , BarreiroP , RendonAet al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis.42(2), 291–295 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S , Martin-CarboneroL , BarreiroPet al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS21(1), 41–46 (2007).
   PubMed Web of Science ®Google Scholar
• D’avolio A , CarcieriC , CusatoJet al. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J. Antimicrob. Chemother.69(11), 3061–3066 (2014).
   PubMed Web of Science ®Google Scholar
• Park WB , ChoePG , SongK-Het al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1* 28 allele frequency. Clin. Infect. Dis.51(1), 101–106 (2010).
   PubMed Web of Science ®Google Scholar
• Griffin L , AnnaertP , BrouwerKL. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J. Pharm. Sci.100(9), 3636–3654 (2011).
   PubMed Web of Science ®Google Scholar
• Rakhmanina NY , NeelyMN , Van SchaikRHet al. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther. Drug Monit.33(4), 417–424 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang X , TierneyC , AlbrechtMet al. Discordant associations between SLCO1B1 521T-->C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. Ther. Drug Monit.35(2), 209–216 (2013).
   PubMed Web of Science ®Google Scholar
• Kohlrausch FB , DeCassia Estrela R , BarrosoPF , Suarez-KurtzG. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br. J. Clin. Pharmacol.69(1), 95–98 (2010).
   PubMed Web of Science ®Google Scholar
• Hartkoorn RC , KwanWS , ShallcrossVet al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics20(2), 112–120 (2010).
   PubMed Web of Science ®Google Scholar
• Castillo-Mancilla JR , AquilanteCL , WempeMFet al. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J. Antimicrob. Chemother.71(6), 1609–1618 (2016).
   PubMed Web of Science ®Google Scholar
• Ihunnah CA , JiangM , XieW. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim. Biophys. Acta1812(8), 956–963 (2011).
   PubMed Web of Science ®Google Scholar
• Siccardi M , D’AvolioA , BaiettoLet al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→ T) with reduced concentrations of unboosted atazanavir. Clin. Infect. Dis.47(9), 1222–1225 (2008).
   PubMed Web of Science ®Google Scholar
• Schipani A , SiccardiM , D’AvolioAet al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob. Agents Chemother.54(12), 5242–5250 (2010).
   PubMed Web of Science ®Google Scholar
• Bunupuradah T , KiertiburanakulS , AvihingsanonAet al. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Lancet HIV3(8), e343–350 (2016).
   PubMed Web of Science ®Google Scholar
• Burger D , TeulenM , EerlandJ , HarteveldA , AarnoutseR , TouwD. The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program. Ther. Drug Monit.33(2), 239–243 (2011).
   PubMed Web of Science ®Google Scholar
• Solas C , SimonN , DrogoulMPet al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br. J. Clin. Pharmacol.64(3), 353–362 (2007).
   PubMed Web of Science ®Google Scholar
• Bertrand J , TreluyerJM , PanhardXet al. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur. J. Clin. Pharmacol.65(7), 667–678 (2009).
   PubMed Web of Science ®Google Scholar
• Estrela RC , SantoroAB , BarrosoPF , TuyamaM , Suarez-KurtzG. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clin. Pharmacol. Ther.84(2), 205–207 (2008).
   PubMed Web of Science ®Google Scholar
• Niemi M , PasanenMK , NeuvonenPJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev.63(1), 157–181 (2011).
   PubMed Web of Science ®Google Scholar
• Gong IY , KimRB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab. Pharmacokinet.28(1), 4–18 (2013).
   PubMed Web of Science ®Google Scholar
• Schipani A , EganD , DickinsonLet al. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antivir. Ther.17(5), 861–868 (2012).
   PubMed Web of Science ®Google Scholar
• Rekic D , CleweO , RoshammarDet al. Bilirubin – a potential marker of drug exposure in atazanavir-based antiretroviral therapy. AAPS J.13(4), 598–605 (2011).
   PubMed Web of Science ®Google Scholar
• Chiou WJ , DeMorais SM , KikuchiR , VoormanRL , LiX , BowDA. In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica44(3), 276–282 (2014).
   PubMed Web of Science ®Google Scholar
• Boffito M , JacksonA , AmaraAet al. Pharmacokinetics of once-daily darunavir–ritonavir and atazanavir–ritonavir over 72 hours following drug cessation. Antimicrob. Agents Chemother.55(9), 4218–4223 (2011).
   PubMed Web of Science ®Google Scholar
• Jittikoon J , MahasirimongkolS , CharoenyingwattanaAet al. Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. J. Hum. Genet.61(2), 119–127 (2016).
   PubMed Web of Science ®Google Scholar